Press Release- 2013
Nes-Ziona, 21st Oct, 2013. Vaxil receives approval for a trial using ImMucin in patients with metastatic breast cancer Read More
For further details see the attached PDF file.
Read More
Nes-Ziona, 12th June, 2013.Vaxil reports promising results from its VAXIL-002 follow-up clinical trial of ImMucin in multiple myeloma patients Read More
For further details see the attached PDF file.
Read More
Nes-Ziona, 9th April, 2013. Vaxil Reports Positive Results From a Phase I/II Clinical Trial Using Its Therapeutic Cancer Vaccine, ImMucin, In Patients With Multiple Myeloma Read More
For further details see the attached PDF file.
Read More
Nes-Ziona, 23th January, 2013. Vaxil Bio Ltd. announced a Collaboration with the University of Santiago de Compostela, Spain Read More
For further details see the attached PDF file.
Read More
Nes-Ziona, 21st January, 2013. Vaxil Bio Ltd. announced today that it is being moved up to Full Main Board Listing on the Tel Aviv Stock Exchange (TASE) Read More
For further details see the attached PDF file.
Read More
|